HomeCompareORYZF vs ADC

ORYZF vs ADC: Dividend Comparison 2026

ORYZF yields 59.88% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ORYZF wins by $468.8K in total portfolio value
10 years
ORYZF
ORYZF
● Live price
59.88%
Share price
$3.34
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$647.7K
Annual income
$151,154.17
Full ORYZF calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — ORYZF vs ADC

📍 ORYZF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORYZFADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORYZF + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ORYZF pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORYZF
Annual income on $10K today (after 15% tax)
$5,089.82/yr
After 10yr DRIP, annual income (after tax)
$128,481.04/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, ORYZF beats the other by $59,803.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORYZF + ADC for your $10,000?

ORYZF: 50%ADC: 50%
100% ADC50/50100% ORYZF
Portfolio after 10yr
$413.3K
Annual income
$115,975.74/yr
Blended yield
28.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

ORYZF
No analyst data
Altman Z
4.4
Piotroski
2/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORYZF buys
0
ADC buys
0
No recent congressional trades found for ORYZF or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORYZFADC
Forward yield59.88%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$647.7K$178.9K
Annual income after 10y$151,154.17$80,797.29
Total dividends collected$536.9K$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: ORYZF vs ADC ($10,000, DRIP)

YearORYZF PortfolioORYZF Income/yrADC PortfolioADC Income/yrGap
1← crossover$16,688$5,988.02$10,990$580.36+$5.7KORYZF
2$27,195$9,339.09$12,301$860.26+$14.9KORYZF
3$43,323$14,223.60$14,104$1,298.62+$29.2KORYZF
4$67,531$21,176.11$16,691$2,008.16+$50.8KORYZF
5$103,108$30,849.85$20,580$3,205.09+$82.5KORYZF
6$154,347$44,020.82$26,754$5,330.02+$127.6KORYZF
7$226,736$61,585.45$37,196$9,345.14+$189.5KORYZF
8$327,159$84,550.92$56,244$17,523.09+$270.9KORYZF
9$464,078$114,017.62$94,286$35,736.21+$369.8KORYZF
10$647,717$151,154.17$178,949$80,797.29+$468.8KORYZF

ORYZF vs ADC: Complete Analysis 2026

ORYZFStock

Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

Full ORYZF Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this ORYZF vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORYZF vs SCHDORYZF vs JEPIORYZF vs OORYZF vs KOORYZF vs MAINORYZF vs NNNORYZF vs EPRTORYZF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.